Anna Johnson, DO
Hematology & Oncology · Pikeville, KYNPI 1912342510
Payments from drug & device makers
Across 148 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$375
- Daiichi Sankyo Inc.$338
- Novartis$308
- Pfizer$283
- AbbVie$274
- AstraZeneca$259
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,74493%
- Education$1947%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 17 | $375 |
| Daiichi Sankyo Inc. | 21 | $338 |
| Novartis | 16 | $308 |
| Pfizer | 17 | $283 |
| AbbVie(2 entities) | 15 | $274 |
| AstraZeneca | 10 | $259 |
| Johnson & Johnson | 11 | $227 |
| Astellas Pharma US Inc | 5 | $150 |
| Boehringer Ingelheim | 5 | $101 |
| Incyte Corporation | 5 | $96 |
| Gilead | 1 | $85 |
| GSK | 4 | $73 |
| Exelixis Inc. | 3 | $48 |
| Bristol Myers Squibb | 2 | $41 |
| Genmab U.S., Inc. | 2 | $40 |
| Genentech USA, Inc. | 3 | $39 |
| Amgen | 1 | $35 |
| Stemline Therapeutics Inc. | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Legend Biotech USA Inc. | 1 | $18 |
| Celltrion USA Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Sanofi | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
How this compares
$2,938 in reported general payments places this provider in the 25th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 35 | $4,525 |
| Prochlorperazine Maleate | 39 | $578 |
| Oxycodone Hcl | 27 | $466 |
| Ondansetron OdtOndansetron | 11 | $346 |
| Gabapentin | 18 | $239 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $135 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $124 |
| Levothyroxine Sodium | 15 | $124 |
| Anastrozole | 11 | $98 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Pikeville
- Christopher CrootPikeville$573K
- Aasems JacobPikeville$236K
- Mohamed El DinaliPikeville$18K
- Joseph MalyLouisville$7M
- Firas BadinLexington$6.7M
- Laila AgrawalLouisville$6.3M
- Jaspreet GrewalLouisville$4.2M
- John VillanoLexington$3.2M
- Rebecca RedmanLouisville$2.1M
- Vivek SharmaLouisville$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.